Log In
Print
BCIQ
Print
Print this Print this
 

pembrolizumab (MK-3475) (formerly lambrolizumab)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHumanized IgG4 mAb against PD-1 receptor (PDCD1; PD-1; CD279)
Molecular Target Programmed cell death 1 (PDCD1) (PD-1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today